

# **Diabetic Retinopathy – Guideline Committee Meeting 5**

Date: 18<sup>th</sup> October 2022

**Location:** Virtual Meeting via Zoom

Minutes: Final

Committee members present:		
Mike Burdon (Chair)	Present for all items	
Philip Burgess	Present for all items	
Rosalind Creer	Present for all items	
Christiana Dinah	Present for all items	
Noemi Lois	Present for all items	
Diva Shah	Present for all items	
Bernadette Warren	Present for all items	
Becky Wei Luo	Present for all items	

In attendance:		
Keona Bennett	Administrator, Guideline Development Team	Present for item 1
Catrina Charlton	Guideline Commissioning Manager	Present for all items
Clare Dadswell	Senior Technical Analyst, Guideline Development Team  Present for all items	
Kirsty Luckham	Technical Analyst (Health Economics)	Present for all items
Syed Mohiuddin	Technical Adviser (Health Economics)	Present for all items
Adam O'Keefe	Project Manager, Guideline Development Team	Present for all items
Hannah Tebbs	Technical Analyst (Health Economics)	Present for all items
Philip Williams	Resource Impact Lead, NICE	Present for all items
Ahmed Yousef	Technical Analyst , Guideline Development Team	Present for all items

Apologies:	
John Anderson	Committee Member
Astrid Aregui	Senior Medical Editor, NICE
Amandeep Bedi	Committee Member
Yvonne Coalbran	Committee Member
Louis Savage	Committee Member

# 1. Welcome and objectives for the meeting

The Chair welcomed the committee members and attendees to the 5<sup>th</sup> meeting on Diabetic Retinopathy. The committee members and attendees introduced themselves.

The Chair informed the Committee that apologies had been received, these are noted above.

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Diabetic Retinopathy. The Chair asked everyone to verbally declare any new interests that are not listed in the registry. The declarations are as follows:

Christiana Dinah advised the committee that she participated in a lecture and debate on *The role of inflammation in Retinal vein occlusion*. Euretina, 01 September 2022 Lecture organised by AbbVie. Non-financial and non-promotional

The Chair advised that this and the interests previously declared did not prevent the attendees from fully participating in the meeting.

The Chair then outlined the objectives for the meeting.

# 2. Rapid glucose lowering (RQ3)

- Evidence reviews
- Economic evidence

The Chair introduced Ahmed Yosef and Hannah Tebbs, who presented the evidence reviews and health economic evidence on rapid glucose lowering (RQ3).

The committee had the opportunity to give feedback and ask questions.

# 3. Discussion of evidence and recommendation drafting (RQ3)

The committee discussed the evidence presented and the recommendations were drafted for (RQ3).

## 4. Treatment thresholds (RQ2)

- Evidence review
- Economic evidence

Ahmed Yosef and Hannah Tebbs presented the evidence review and health economic evidence on treatment thresholds (RQ2).

The committee had the opportunity to give feedback and ask questions.

# 5. Continued discussion and recommendation drafting RQ2

The committee discussed the evidence presented and the recommendations were drafted for RQ2.

#### 6. Short presentation on vitrectomy

The Chair introduced Noemi Lois, who presented a short presentation on Vitrectomy. The committee had the opportunity to engage and give feedback.

## 7. Update on RQ6 - What is the effectiveness of vitrectomy surgery alone, or in

# combination with other treatments for treating proliferative diabetic retinopathy and macular oedema

Ahmed Yosef gave an update on RQ6. The committee had the opportunity to give feedback and ask questions.

# 8. Short HE presentation

Hannah Tebbs gave a short health economics presentation. The committee had the opportunity to give feedback and ask questions.

# 9. AOB, summary and next steps

The Chair confirmed the next meeting date, next steps and thanked those present for their contributions. The meeting concluded.